Trials / Completed
CompletedNCT03736733
Relevance of an Adapted and Supervised Physical Activity Program in Fibromyalgia Patients. The FIMOUV 1 Study.
Relevance of an Adapted and Supervised Physical Activity Program in Fibromyalgia Patients. The FIMOUV 1 Study. Interventional, Controlled, Randomized, Open Study of an Original Outpatient Management.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Fibromyalgia affects 2 to 5% of adults in the general population. Patients describe a combination of symptoms centred around fatigue not induced by exercise and not relieved by rest. The diagnosis of fibromyalgia is self-perpetuating by the deconditioning, consequence of a reduced muscle mass due to inactivity and periods of prolonged rest. Thus, it seems fundamental to develop other non-drug approaches: among them, adapted physical activity is recommended by most learned societies because of a good level of evidence (Level 1, Grade A). The question remains, however, whether simple advice to resume physical activity is sufficient (routine care with medical assessment at 3 months) or whether a physical activity supervised inside and outside the hospital is not more relevant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | physical activity program | Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified "Sports Health" in the Loire (42) or Haute-Loire (43) for 2 months. |
| OTHER | Advice and recommendations of physical activity at home | Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy). |
Timeline
- Start date
- 2018-11-15
- Primary completion
- 2019-12-19
- Completion
- 2021-06-11
- First posted
- 2018-11-09
- Last updated
- 2022-09-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03736733. Inclusion in this directory is not an endorsement.